TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"

TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)" - BRAVERY TR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031552

Enrollment

Registered

2018-03-26

Start date

2018-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRAF V600E mutant metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Enrolled in the BRAVERY study 2) Written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency	—

Countries

Japan

Contacts

Public ContactToshiki Masuishi

Aichi Cancer Center Hospital Department of Clinical Oncology

BRAVERY_core@east.ncc.go.jp052-764-6111

Outcome results